Methods and products for diagnosing autoimmune disease and gastric cancer linked with atrophic gastritis
AssigneeBiohit Oyj
InventorOsmo Suovaniemi
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for examining a person having symptoms and/or biomarkers indicating an autoimmune disease for the presence of atrophic gastritis. The biomarker combination, which diagnoses atrophic gastritis, acts also as a part of a biomarker panel that helps diagnosis and assessment of autoimmune disease as well. The invention relates also to products used in these methods.
Claims12
A method for determining the presence of Helicobacter pylori infection and/or atrophic gastritis in a person diagnosed as having symptoms of diabetes mellitus type 1, said method comprising the steps of:
- a) obtaining a biological sample from the person diagnosed as having symptoms of diabetes mellitus type 1;
- b) quantitatively measuring a plurality of biomarkers from said biological sample with a non-invasive test(s), wherein said plurality of biomarkers comprises pepsinogen I, pepsinogen II, pepsinogen I/II ratio, gastrin-17 and Helicobacter pylori antibodies, and wherein the pepsinogen I, pepsinogen II and gastrin-17 are measured using an antibody;
- c) comparing the values obtained to cut-off values or reference ranges;
- and
- d) determining that said person diagnosed as having symptoms of diabetes mellitus type 1 has a Helicobacter pylori infection and/or atrophic gastritis, based on said comparing.
A method for determining whether a person having a Helicobacter pylori infection and/or atrophic gastritis has diabetes mellitus type I, said method comprising the steps of:
- a) obtaining a biological sample from a person;
- b) quantitatively measuring a plurality of biomarkers from said biological sample with a non-invasive test(s), wherein said plurality of biomarkers comprises pepsinogen I, pepsinogen II, pepsinogen I/II ratio, gastrin-17 and Helicobacter pylori antibodies, and wherein the pepsinogen I, pepsinogen II and gastrin-17 are measured using an antibody;
- c) comparing the values obtained to cut-off values or reference ranges, and determining that said person has a Helicobacter pylori infection and/or atrophic gastritis based on said comparing;
- d) examining said person for the presence of symptoms indicative of diabetes mellitus type I when said person is determined to have a Helicobacter pylori infection and/or atrophic gastritis;
- and
- e) determining that said person has diabetes mellitus type I when said person has symptoms indicative of diabetes mellitus type I.
Dependencies are inferred from the claim text.